Our Story
While working as a scientist at Los Alamos National Laboratory (LANL), Dr. Alex Koglin developed two compounds to create a better vaccine for Tuberculosis (TB). In 2015, Dr. Koglin took an entrepreneurial leave of absence from LANL to start Nature’s Toolbox, Inc. (NTx). His objective was to develop and commercialize a TB treatment based on two antibiotic compounds he created during his time in Los Alamos. In 2018 alone, a total of 1.5 million people died from TB. According to the World Health Organization, TB is the leading infectious disease resulting in death worldwide. Approximately one-quarter of the world’s population is infected with mycobacterium tuberculosis, the bacteria that causes TB.
World Changing. Life Saving. For Good.
NTx began production of the compounds using current manufacturing processes. Using these processes, NTx could not produce the compounds at a reasonable price for patients in third world countries. That is when the company shifted to developing a new methodology, “in vitro synthetic biology”, to increase production of these difficult-to-make compounds.
To accomplish this, the NTx team initially turned to existing cell-free expression systems; however, they quickly pivoted to developing their own recombinant continuous flow method. This work became the technology platform, NTxpress®. With the recent pandemic emerging, the team quickly understood the importance of their system and complemented the first platform with a second, NTxscribe®, to produce mRNA-based products utilizing transcription, the first step in protein translation.
Today, the company is advancing the healthcare industry with their cutting-edge biomanufacturing solutions, NTxpress® and NTxscribe®, to create life-saving medicines in an eco-friendly and sustainable way.
SUSTAINABLE
Our biosynthesis technology is completely defined and is independent of cell lines
CONSISTENT
Our results are reproducible with limited artifacts
SCALABLE
Our biomanufacturing processes can be easily scaled to meet fluctuating supply needs
BIOSYNTHETIC
Our platforms are built for mRNA and proteins that are made in-vitro and not expressed in cells
EFFICIENT
Rapid, high-quality, and low-cost production to accelerate lead optimization, pre-clinical testing and IND filings
EXECUTIVE LEADERSHIP
Steven Evans, PhD
Chief Scientific Officer and Senior Vice President of R&D
Marcel Roche
Chief Financial Officer
Sheila Moran
Chief Commercial Officer
Matthew Phillips
Senior Vice President, Strategic Alliances
Mark Brancieri
Vice President, Manufacturing
Phillip Easton, PhD
Vice President, IT Infrastructure and Operations